All In Biotech

Drug Trial Radar · NCT05682482

LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

A National Randomized Placebo-controlled Double-blind Multicenter Trial of LT4/LT3 Combination Therapy in Patients with Autoimmune Hypothyroidism: the T3-4-Hypo Trial.

Last checked: Nov 20, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 7, 2022

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
M. MediciAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development; ACE Pharmaceuticals BV
First posted
Jan 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This could be explained by the fact that physiological T4/T3 ratios cannot be reached with LT4 monotherapy, as in a healthy individual T3 is not only derived from T4/T3 conversion but is also directly produced by the thyroid itself. Studies have reported contradicting results as to whether addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy is effective or not. Studies have suggested higher effectiveness in patients carrying genetic variation in the type 2 deiodinase (DIO2-rs225014) and monocarboxylate transporter 10 (MCT10-rs17606253) genes. Objective: To investigate whether addition of liothyronine (LT4/LT3 combination therapy) in in patients with persistent tiredness on LT4 monotherapy is effective or not in relieving tiredness.

Conditions

  • Autoimmune Hypothyroidism

Interventions

  • LT3 (liothyronine)Drug

    Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.

  • PlaceboDrug

    Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline to 52 weeks in the ThyPRO tiredness subscale scores.Time frame: 52 weeks
  2. Effect sizes in genetic subgroupsTime frame: 52 weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Flevoziekenhuis

    Almere Stad, Netherlands · Recruiting

  • Amsterdam UMC - Location AMC

    Amsterdam, Netherlands · Recruiting

  • Gelre ziekenhuizen

    Apeldoorn, Netherlands · Not yet recruiting

  • Rijnstate

    Arnhem, Netherlands · Recruiting

  • Amphia ziekenhuis

    Breda, Netherlands · Recruiting

  • Van Weel-Bethesda Hospital

    Dirksland, Netherlands · Recruiting

  • Albert Schweitzer Hospital

    Dordrecht, Netherlands · Recruiting

  • Treant

    Emmen, Netherlands · Not yet recruiting

  • Admiraal de Ruyter Hospital

    Goes, Netherlands · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Saxenburgh MC

    Hardenberg, Netherlands · Recruiting

  • Radboudumc

    Nijmegen, Netherlands · Recruiting

  • Erasmus Medical Center

    Rotterdam, Netherlands · Recruiting

  • Maasstad Hospital

    Rotterdam, Netherlands · Recruiting

  • Franciscus Gasthuis & Vlietland

    Schiedam, Netherlands · Recruiting

  • Zuyderland

    Sittard, Netherlands · Recruiting

  • University Medical Center Utrecht

    Utrecht, Netherlands · Recruiting

  • Maxima Medical Center

    Veldhoven, Netherlands · Recruiting

  • Vie Curie MC

    Venlo, Netherlands · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.